Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

NeuroOne Medical Shares Fall After EEG Electrode Regulatory Update

Author: Vandana Singh | August 09, 2022 01:16pm

  • NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) has submitted a special 510(k) to the FDA for its sEEG electrode to extend the duration of use from less than 24 hours to less than 30 days use. 
  • According to FDA guidance, a special 510(k) is usually reviewed within 30 days of receipt, rather than the 90 days for a traditional 510(k).
  • NeuroOne Medical is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation, and ablation solutions.
  • In May, the FDA stated that they upheld their decision that the device is not substantially equivalent for extended use based on their analysis of the methodology used for exhaustive extraction testing.
  • Today, the agency informed the company that it could submit a new 510(k) with new evidence, specifically regarding the subacute toxicity biocompatibility endpoint.
  • Last week, NeuroOne announced a $3.5 million accelerated milestone payment from Zimmer Biomet Holdings Inc (NYSE: ZBH). The amendment will also give Zimmer 350,000 warrants with an exercise price of $3.00 per share.
  • Price Action: NMTC shares are down 5.80% at $1.79 during the market session on the last check Tuesday.

Posted In: NMTC ZBH

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist